Interview with CAR T cell expert Dr. Michel Sadelain in Human Gene Therapy
Share

IMAGE: Human Gene Therapy presents reports on the transfer and expression of genes in mammals, including humans. view more 

Credit: Mary Ann Liebert, Inc., publishers

New Rochelle, NY, May 18, 2018–Michel Sadelain, MD, PhD, Director, Center for Cell Engineering, Memorial Sloan-Kettering Cancer Center in New York City, offers a fasci-nating perspective on the remarkable progress being made in the field of chimeric antigen receptor (CAR) engineered T-cell therapies to treat cancer. A lively and informative inter-view with Dr. Sadelain in which he also describes his leading role in advancing this rap-idly evolving field, is published in Human Gene a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free for download on the Human Gene Therapy website until June 18, 2018.

Jennifer Adair, PhD, Fred Hutchinson Cancer Research Center (Seattle, WA), conduct-ed the interview with Dr. Sadelain ( asking him to trace the stunning events that led to FDA approval of the first CAR T-cell therapy last summer to treat acute lymphoblastic leukemia (ALL). Dr. Sadelain recounts his early interest and ongoing research in CAR T-cell engineering and shares his views on what next-generation CAR technology will look like and what are the greatest challenges and

read more...


Article originally posted at
www.eurekalert.org

Click here for the full story


CategoryAggregator News

© 2017 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

Powered by MMD